Skip to main content
Fig. 6 | Journal of Biomedical Science

Fig. 6

From: mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications

Fig. 6

Development status and global sales forecast for mRNA-based drugs. A Composite development status of 316 mRNA-based medicines (excluding technologies that were discontinued, suspended or not updated for an extended period); analyzed with Clarivate’s Cortellis Competitive Intelligence Database on July 28, 2023. B–D Global sales forecasts to 2029 are based on analyst consensus, acquired from GlobalData’s Intelligence Center Database on June 26, 2023. B Five FDA-approved ASO (anti-sense oligo) drugs. C Five FDA-approved siRNA drugs. D Two FDA-approved mRNA vaccines are available on the market. Summary information regarding these drugs is provided in "Regulatory agency-approved drugs". Regulatory agency-approved drugs. E–G Total global sales forecasts (US$ million) for each drug up to 2029

Back to article page

Journal of Biomedical Science

ISSN: 1423-0127